An RCT finds adding semaglutide to metformin improves weight, testosterone, and natural pregnancy rates in women with PCOS. PICO summary and expert commentary.
Browsing: GLP-1 Receptor Agonists
Clinical trial summaries for GLP-1 receptor agonists, including cardiovascular outcomes, glycaemic control, obesity, kidney outcomes, tolerability, and practice implications.
An RCT finds the GLP-1 analogue Ebenatide improves glycaemia, time in range, and body composition in type 2 diabetes, confirming a class effect. PICO summary and commentary.
An acute crossover infusion study (n=8) found exenatide-glucagon co-infusion raised myocardial glucose uptake and a diastolic strain rate marker in type 2 diabetes. PICO summary and expert commentary.
Clinical Context GLP-1 receptor agonists produce substantial weight loss, but the mechanisms underlying this effect have been debated. Is weight…
Clinical Context Heart failure with preserved ejection fraction (HFpEF) represents one of the most challenging conditions in cardiovascular medicine. Unlike…
An exploratory secondary analysis of two Phase 2 trials reports that oral orforglipron lowered blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP versus placebo, though no cardiovascular events were measured. PICO summary and expert commentary.
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 met its equivalence margin for HbA1c reduction against reference dulaglutide. PICO summary and expert commentary.
Summary: In 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30 kg/m²) from the pooled STEP-HFpEF trials, semaglutide 2.4 mg…
Summary: In adults with chronic kidney disease and overweight or obesity but without diabetes, semaglutide 2.4 mg once weekly for…
📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context The GLP-1…